Literature DB >> 20202742

Extracellular ATP enhances in vitro invasion of prostate cancer cells by activating Rho GTPase and upregulating MMPs expression.

Yang Zhang1, Li-hua Gong, Hong-quan Zhang, Qiang Du, Jiang-feng You, Xin-xia Tian, Wei-gang Fang.   

Abstract

We previously found that in addition to anti-proliferation function, extracellular ATP had a pro-invasion effect on prostate cancer cells, and probably serves as an important regulator of invasion in local microenvironment. However, the underlying mechanism remains unclear. In this study, we demonstrated that ATP increased the motility of prostate cancer cells, and promoted formation of lamellipodia and filopodia. We also found that ATP induced activation of Rac1 and Cdc42, and promoted expression of MMP-3 and MMP-13. These data suggest that extracellular ATP enhances the invasion of prostate cancer cells by activating Rho GTPases Rac1 and Cdc42 and upregulating MMPs expression. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20202742     DOI: 10.1016/j.canlet.2010.01.010

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  28 in total

1.  The P2Y2 nucleotide receptor mediates the proliferation and migration of human hepatocellular carcinoma cells induced by ATP.

Authors:  Rui Xie; Jingyu Xu; Guorong Wen; Hai Jin; Xuemei Liu; Yuan Yang; Bei Ji; Yixia Jiang; Penghong Song; Hui Dong; Biguang Tuo
Journal:  J Biol Chem       Date:  2014-05-20       Impact factor: 5.157

2.  Bergamottin, a natural furanocoumarin abundantly present in grapefruit juice, suppresses the invasiveness of human glioma cells via inactivation of Rac1 signaling.

Authors:  Wenzheng Luo; Zhenyu Song; Hongwei Sun; Junxin Liang; Shanshan Zhao
Journal:  Oncol Lett       Date:  2017-12-19       Impact factor: 2.967

Review 3.  Purinergic signalling and cancer.

Authors:  Geoffrey Burnstock; Francesco Di Virgilio
Journal:  Purinergic Signal       Date:  2013-12       Impact factor: 3.765

4.  Traumatic noise activates Rho-family GTPases through transient cellular energy depletion.

Authors:  Fu-Quan Chen; Hong-Wei Zheng; Kayla Hill; Su-Hua Sha
Journal:  J Neurosci       Date:  2012-09-05       Impact factor: 6.167

5.  High dose of extracellular ATP switched autophagy to apoptosis in anchorage-dependent and anchorage-independent hepatoma cells.

Authors:  Qing Wei; Ying Zhang; Lei Sun; Xiaoqing Jia; Wanwan Huai; Chengcheng Yu; Zhengkun Wan; Lihui Han
Journal:  Purinergic Signal       Date:  2013-06-19       Impact factor: 3.765

6.  P2X7 Receptor Function in Bone-Related Cancer.

Authors:  Elena Adinolfi; Francesca Amoroso; Anna Lisa Giuliani
Journal:  J Osteoporos       Date:  2012-08-16

7.  Nucleotide receptors as targets in the pharmacological enhancement of dermal wound healing.

Authors:  Edyta Gendaszewska-Darmach; Marta Kucharska
Journal:  Purinergic Signal       Date:  2011-04-26       Impact factor: 3.765

8.  Remodeling of purinergic receptor-mediated Ca2+ signaling as a consequence of EGF-induced epithelial-mesenchymal transition in breast cancer cells.

Authors:  Felicity M Davis; Paraic A Kenny; Eliza T-L Soo; Bryce J W van Denderen; Erik W Thompson; Peter J Cabot; Marie-Odile Parat; Sarah J Roberts-Thomson; Gregory R Monteith
Journal:  PLoS One       Date:  2011-08-05       Impact factor: 3.240

9.  The lysosomal TRPML1 channel regulates triple negative breast cancer development by promoting mTORC1 and purinergic signaling pathways.

Authors:  Mengnan Xu; Shekoufeh Almasi; Yiming Yang; Chi Yan; Andra Mihaela Sterea; Alia Kazim Rizvi Syeda; Bing Shen; Clements Richard Derek; Peng Huang; Shashi Gujar; Jun Wang; Wei-Xing Zong; Mohamed Trebak; Yassine El Hiani; Xian-Ping Dong
Journal:  Cell Calcium       Date:  2019-03-02       Impact factor: 4.690

Review 10.  Many faces of DAMPs in cancer therapy.

Authors:  O Krysko; T Løve Aaes; C Bachert; P Vandenabeele; D V Krysko
Journal:  Cell Death Dis       Date:  2013-05-16       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.